Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,564.47
-8.3350-0.53%
Number of Gainers:1
Number of Losers:6
Number of Flat:- -
PE:- -
High:1,591.44
Open:1,573.14
Low:1,558.99
Close:1,572.81
Volume:60.44M
Turnover:4.79B
Market Cap:1.63T
Float Cap:1.57T

Loading ...

BMO Capital Adjusts Price Target on Pfizer to $35 From $30, Keeps Outperform Rating

MT Newswires Live
·
Sep 09

Sino Biopharmaceutical Stock Slides 4.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 09

LIVE Markets-Europe Before the Bell: Eyeing Another Soft Open

Reuters
·
Sep 09

Amgen Shares Plunge to Decade Low After Rival Drug Trial Fails, BMO Cuts Rating

Stock News
·
Sep 09

Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Beam Therapeutics (BEAM) and Royalty Pharma (RPRX)

TIPRANKS
·
Sep 09

NYSE Most Active Issues

Dow Jones
·
Sep 09

Money Quote: a Bad Day for Amgen Stock

Dow Jones
·
Sep 09

Atai Beckley Holds Shareholder Meeting, Quorum Met with 65.6% Shares Represented

Reuters
·
Sep 09

Pfizer Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 09

AMD, Amgen, Novartis, Qualcomn, Corning, and More Stocks That Explain Today's Market

Dow Jones
·
Sep 09

LIVE Markets-Back to the Post-Summer Grind: Stocks End Red

Reuters
·
Sep 09

Novo Nordisk A/S Stock (NVO) Closed Down by 3.09% on Sep 8: Facts Behind the Movement

TradingKey
·
Sep 09

US Equity Markets End Lower After Houthi Attack on Saudi Arabia Energy Facilities

MT Newswires Live
·
Sep 09

Structure Falls as Investors Await More Obesity Trial Data, Says Jefferies

Reuters
·
Sep 09

Amgen Stock Poised for Worst Day in More than Two Decades

Dow Jones
·
Sep 09

Eli Lilly Stock (LLY) Falls on Competitor Novartis’ Cholesterol Drug Setback

TIPRANKS
·
Sep 09

Top Midday Decliners

MT Newswires Live
·
Sep 09

GLP1 Drugs Work for Kids, Says Novo Nordisk. They Could be Another Huge Market.

Dow Jones
·
Sep 09

Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says

MT Newswires Live
·
Sep 09

Royalty Pharma Falls After Novartis' Cholesterol Drug Fails in Study

Reuters
·
Sep 09